Positron Emission Tomography News and Research

RSS

Cosmochemistry techniques shed light on potential new Alzheimer's disease biomarker

The study identifies lower potassium isotope ratios in Alzheimer's patients, suggesting δ41K as a viable biomarker for early detection of the disease.

9 Sep 2024

American football head impacts tied to increased brain damage and cognitive decline

Repetitive head impacts in former American football players are linked to increased perivascular space volume, which correlates with cognitive decline and neurodegeneration. The study suggests that the force of head impacts may be more critical than frequency, with potential protective effects from β-blocker use.

1 Sep 2024

New ESC guidelines highlight broader approach to managing chronic coronary syndromes

The 2024 ESC Guidelines on the management of chronic coronary syndromes (CCS) include a focus on both larger and smaller blood vessels of the heart; new models to estimate chances of blocked large arteries (so-called obstructive coronary artery disease); optimal selection and sequence of tests; drugs and interventions to prevent disease complications and improve symptoms, and the fundamental role of patient involvement.

30 Aug 2024

PET imaging and proteomics reveal distinct protein signatures in Alzheimer's disease progression

Researchers used PET imaging and proteomic analysis of cerebrospinal fluid to study amyloid β and tau tangle loads in Alzheimer's patients, identifying 127 proteins linked to disease progression. The findings highlight distinct molecular pathways and potential therapeutic targets.

28 Aug 2024

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Researchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.

26 Aug 2024

Engineered human cardiac tissue reveals how lupus autoantibodies damage the heart

Study demonstrates that autoantibodies in systemic lupus erythematosus (SLE) patients contribute to myocardial injury by binding to and impairing stressed cardiac cells, offering insights into potential therapeutic targets.

25 Aug 2024

Researchers develop four new regimens to treat people with multidrug-resistant TB meningitis

In a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children's Center say they have developed four new regimens that have the potential to treat and save the lives of people with multidrug-resistant (MDR) tuberculous (TB) meningitis.

16 Aug 2024

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Researchers highlighted the complexities of using amyloid immunotherapy for early Alzheimer's disease, discussing its clinical benefits, challenges, and broader health implications. Despite some positive results, concerns over adverse effects, trial biases, and cost hinder widespread adoption.

7 Aug 2024

New dual-purpose contrast agent revolutionizes PET and MRI integration for enhanced diagnosis

A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can be used in both magnetic resonance imaging (MRI) and positron emission tomography (PET).

5 Aug 2024

Active immune cells discovered in brain's cranial bone marrow fighting glioblastomas

A study uncovers the presence and activity of immune cells in glioblastoma, revealing new insights into brain tumor immunology and potential treatment avenues.

4 Aug 2024

New blood test achieves 90% accuracy in diagnosing Alzheimer’s disease, outperforms doctors

Researchers in Sweden developed a combined blood test with up to 90% accuracy for diagnosing Alzheimer's disease, surpassing the diagnostic rates of primary care doctors and specialists.

29 Jul 2024

Comprehensive dataset from A4 study yields key insights about Alzheimer's disease

Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study, the first and largest clinical trial of pre-symptomatic Alzheimer's disease, is now widely available to researchers studying the condition.

24 Jul 2024

A reliable artificial intelligence-guided marker for early dementia prediction

Researchers use machine learning techniques to develop and test a predictive prognostic model to predict dementia early using real-world patient data.

18 Jul 2024

Predicting Alzheimer's decline: New model offers personalized insights for patients

Researchers developed a model to predict cognitive decline in Alzheimer's patients using clinical and biomarker data, improving personalized treatment plans.

16 Jul 2024

Immunotherapy response assessment in malignant pleural mesothelioma: FDG-PET/CT vs. CT

A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma."

15 Jul 2024

Revolutionary AI model improves early dementia diagnosis

Cambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease.

13 Jul 2024

Researchers develop a more accurate way to scan for tuberculosis using PET

A more accurate way to scan for tuberculosis (TB) has been developed by UK and US researchers, using positron emission tomography (PET).

27 Jun 2024

Blood-based biomarkers could revolutionize Alzheimer's diagnosis and treatment

A recent review outlines the necessary factors for widespread implementation and interpretation of Alzheimer's disease blood-based biomarkers (BBMs) at the population level, emphasizing the potential for early detection and improved diagnosis.

14 Jun 2024

UC Davis pioneers advanced PET imaging to monitor lung cancer treatment

Lung cancer can advance quickly. Once a person starts treatment, it is vital to know if that treatment is working or if the patient should be switched to a different treatment.

10 Jun 2024

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.

28 May 2024